We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
Read MoreHide Full Article
Novo Nordisk (NVO - Free Report) closed at $52.39 in the latest trading session, marking a +2.97% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.19%. On the other hand, the Dow registered a gain of 0.66%, and the technology-centric Nasdaq decreased by 0.03%.
Shares of the drugmaker have appreciated by 6.02% over the course of the past month, outperforming the Medical sector's gain of 0.17%, and the S&P 500's gain of 0.54%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. In that report, analysts expect Novo Nordisk to post earnings of $0.9 per share. This would mark a year-over-year decline of 1.1%. Simultaneously, our latest consensus estimate expects the revenue to be $12.11 billion, showing a 1.19% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.57 per share and a revenue of $47.95 billion, signifying shifts of +8.84% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.1% lower. Novo Nordisk is currently a Zacks Rank #5 (Strong Sell).
With respect to valuation, Novo Nordisk is currently being traded at a Forward P/E ratio of 14.5. This expresses no noticeable deviation compared to the average Forward P/E of 14.5 of its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 105, this industry ranks in the top 43% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Novo Nordisk (NVO) Outpaced the Stock Market Today
Novo Nordisk (NVO - Free Report) closed at $52.39 in the latest trading session, marking a +2.97% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 0.19%. On the other hand, the Dow registered a gain of 0.66%, and the technology-centric Nasdaq decreased by 0.03%.
Shares of the drugmaker have appreciated by 6.02% over the course of the past month, outperforming the Medical sector's gain of 0.17%, and the S&P 500's gain of 0.54%.
The upcoming earnings release of Novo Nordisk will be of great interest to investors. In that report, analysts expect Novo Nordisk to post earnings of $0.9 per share. This would mark a year-over-year decline of 1.1%. Simultaneously, our latest consensus estimate expects the revenue to be $12.11 billion, showing a 1.19% drop compared to the year-ago quarter.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $3.57 per share and a revenue of $47.95 billion, signifying shifts of +8.84% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Novo Nordisk. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 4.1% lower. Novo Nordisk is currently a Zacks Rank #5 (Strong Sell).
With respect to valuation, Novo Nordisk is currently being traded at a Forward P/E ratio of 14.5. This expresses no noticeable deviation compared to the average Forward P/E of 14.5 of its industry.
The Large Cap Pharmaceuticals industry is part of the Medical sector. With its current Zacks Industry Rank of 105, this industry ranks in the top 43% of all industries, numbering over 250.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.